Cellectar Biosciences, Inc.
CLRB Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$1.22
KIRA · Stoqly’s AI analyst, in plain words
- Cellectar Biosciences, Inc. lost $21.8M in fiscal 2025.
- Free cash flow was −$23.1M in fiscal 2025, — of revenue.
Market cap
$14.9M
P/E
—
Revenue
—
Net income
−$21.8M
Free cash flow
−$23.1M
Operating margin
—
Cellectar Biosciences, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$21.8M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Cellectar Biosciences, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 4, 2026
- Legal name
- Cellectar Biosciences, Inc.
- CIK
- 0001279704
Cellectar Biosciences, Inc. · CLRB
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Net income | −$24.1M | −$31.8M | −$42.8M | −$44.6M | −$21.8M |
| Diluted EPS | −$4.35 | −$4.51 | −$3.50 | −$41.89 | −$8.35 |
| Cash | |||||
| Cash from operations | −$22.6M | −$25.2M | −$32.4M | −$47.6M | −$23.1M |
| Capital expenditure | $0.1M | $0.2M | $0.9M | $0.1M | $0.0M |
| Free cash flow | −$22.7M | −$25.4M | −$33.2M | −$47.7M | −$23.1M |
| Share count change | −72.0% | 27.1% | 73.2% | −89.9% | 110.7% |
| Debt and strength | |||||
| Cash and short-term investments | $35.7M | $19.9M | $9.6M | $23.3M | $13.2M |
| Shareholders' equity | $29.1M | $8.2M | −$15.2M | $14.3M | $8.5M |
| Current ratio | 9.2x | 1.8x | 0.4x | 2.6x | 3.0x |
| Returns and quality | |||||
| Return on equity | −57.5% | −170.9% | — | — | −190.9% |
| Return on tangible equity | −83.0% | −389.9% | — | −311.9% | −255.2% |
| Altman Z'' | −4.5 | −29.7 | −85.1 | −40.0 | −63.0 |
Insiders bought, 12 months
$0.0M
2 insiders
Insiders sold, 12 months
$0.0M
1 insider
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cellectar Biosciences, Inc. · CLRB
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.22 a share, the company is worth $14.9M.
Source: SEC EDGAR XBRL filings (CIK 0001279704). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.